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Cellular immune responses to HCV core increase and HCV RNA
levels decrease during successful antiretroviral therapy
Abstract
BACKGROUND: Hepatitis C virus (HCV) infection is a major cause of morbidity in HIV infected
individuals. Coinfection with HIV is associated with diminished HCV-specific immune responses and
higher HCV RNA levels.
AIMS: To investigate whether long-term combination antiretroviral therapy (cART) restores
HCV-specific T cell responses and improves the control of HCV replication.
METHODS: T cell responses were evaluated longitudinally in 80 HIV/HCV coinfected individuals by
ex vivo interferon-gamma-ELISpot responses to HCV core peptides, that predominantly stimulate
CD4(+) T cells. HCV RNA levels were assessed by real-time PCR in 114 individuals.
RESULTS: The proportion of individuals with detectable T cell responses to HCV core peptides was
19% before starting cART, 24% in the first year on cART and increased significantly to 45% and 49%
after 33 and 70 months on cART (p=0.001). HCV-specific immune responses increased in individuals
with chronic (+31%) and spontaneously cleared HCV infection (+30%). Median HCV RNA levels
before starting cART were 6.5 log(10) IU/ml. During long-term cART, median HCV-RNA levels
slightly decreased compared to pre-cART levels (-0.3 log10 IU/ml, p=0.02).
CONCLUSIONS: Successful cART is associated with increasing cellular immune responses to HCV
core peptides and with a slight long-term decrease in HCV RNA levels. These findings are in line with
the favourable clinical effects of cART on the natural history of hepatitis C and with the current
recommendation to start cART earlier in HCV/HIV coinfected individuals.
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Cellular immune responses to HCV core increase and
HCV RNA levels decrease during successful
antiretroviral therapy
Janine Rohrbach,1 Nicola Robinson,2 Gillian Harcourt,2 Emma Hammond,3
Silvana Gaudieri,3,4 Meri Gorgievski,5 Amalio Telenti,6 Olivia Keiser,7
Huldrych F Gu¨nthard,8 Bernhard Hirschel,9 Matthias Hoffmann,10 Enos Bernasconi,11
Manuel Battegay,12 Hansjakob Furrer,1 Paul Klenerman,2 Andri Rauch,1,3
the Swiss HIV Cohort Study
ABSTRACT
Background Hepatitis C virus (HCV) infection is a major
cause of morbidity in HIV infected individuals. Coinfection
with HIV is associated with diminished HCV-specific
immune responses and higher HCV RNA levels.
Aims To investigate whether long-term combination
antiretroviral therapy (cART) restores HCV-specific T cell
responses and improves the control of HCV replication.
Methods T cell responses were evaluated longitudinally
in 80 HIV/HCV coinfected individuals by ex vivo
interferon-g-ELISpot responses to HCV core peptides,
that predominantly stimulate CD4+ T cells. HCV RNA
levels were assessed by real-time PCR in 114 individuals.
Results The proportion of individuals with detectable T
cell responses to HCV core peptides was 19% before
starting cART, 24% in the first year on cART and
increased significantly to 45% and 49% after 33 and
70 months on cART (p¼0.001). HCV-specific immune
responses increased in individuals with chronic (+31%)
and spontaneously cleared HCV infection (+30%).
Median HCV RNA levels before starting cART were 6.5
log10 IU/ml. During long-term cART, median HCV-RNA
levels slightly decreased compared to pre-cART levels
(0.3 log10 IU/ml, p¼0.02).
Conclusions Successful cART is associated with
increasing cellular immune responses to HCV core
peptides and with a slight long-term decrease in HCV
RNA levels. These findings are in line with the favourable
clinical effects of cART on the natural history of hepatitis
C and with the current recommendation to start cART
earlier in HCV/HIV coinfected individuals.
INTRODUCTION
Hepatitis C is a major cause of morbidity and death
in HIV infected individuals.1 In the Swiss HIV
Cohort Study (SHCS), 33% of HIV infected indi-
viduals are coinfected with the hepatitis C virus
(HCV).2 Coinfection with HIV accelerates the
progression to liver cirrhosis3 and is associated
with higher HCV RNA levels,4 5 particularly in
individuals with low CD4+ T cell counts.6 Cellular
immune responses, crucial for the control of HCV
infection,7 are severely diminished in HIV infected
individuals; HCV-specific CD8+ and CD4+ T cell
responses are weak in chronic hepatitis C and are
further impaired in HIV coinfected individuals.8e10
The loss of cellular immune responses to HCV is
particularly evident in individuals with low CD4+
T cell counts.11 12
Combination antiretroviral therapy (cART)
reduces liver-related mortality in HIV/HCV coin-
fected individuals.13 14 Potential favourable effects
of cART on the course of hepatitis C include
a reduction in immune activation and an increase in
cellular immune responses. It is unclear to what
extent a successful cART restores HCV-specific
immune responses. Previous studies suggested that
HCV RNA levels increase in the first 3e6 months
Significance of this study
What is already known about this subject?
< Coinfection with HIV accelerates the progression
of liver fibrosis in individuals with chronic
hepatitis C.
< Coinfection with HIV is associated with dimin-
ished hepatitis C specific T cell responses and
with higher hepatitis C virus (HCV) RNA levels.
What are the new findings?
< Cellular immune responses to HCV core peptides
increase significantly during successful combi-
nation antiretroviral therapy (cART).
< Immune responses to HCV core peptides during
long term cART are comparable to those in HCV
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< HCV RNA levels slightly decrease long term in
individuals with immune recovery through
a successful cART.
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after the start of cART.15 16 However, it is unclear whether
immune restoration through cART improves the control of HCV
replication long term.17
In this study, we longitudinally investigated the impact of
HIV and of a successful cART on HCV-specific T cell responses
and on HCV RNA levels.
METHODS
Participants and study design
Study participants were included from the Swiss HIV Cohort
Study (SHCS), a prospective multicentre study carried out at
seven major Swiss hospitals and their local affiliated centres.18 19
Written informed consent, including for genetic testing, was
mandatory for inclusion, and the study was approved by all local
ethical committees. Demographic and clinical characteristics
were extracted from clinical databases.
HCV-specific T cell responses and HCV RNA levels were
assessed longitudinally during untreated HIV infection and
during successful cART. Successful cART was defined as HIV-
RNA levels below 400 copies/ml after 6 months from cARTstart
and thereafter. Follow-up was censored at the first virological
failure (HIV-RNA above 1000 cp/ml). Low level viral replication
(HIV-RNA 400e1000 cp/ml) post-cART was present in 2% of
measurements. In these instances, follow-up was not censored
as these events were not considered immunologically relevant.
SHCS participants fulfilling the following criteria were
included: (i) anti-HCV seropositivity (using ELISA and confirmed
by immunoblot or recombinant immunoblot assay (RIBA)) and
detectable HCV RNA, assessed by quantitative or qualitative
assays; and (ii) availability of frozen peripheral blood mono-
nuclear cells (PBMCs) and/or plasma samples before commence-
ment of cART (median 0.8 (IQR 4 to 0.2) months pre-cART) and
after more than 2 years of successful cART (median 33 (IQR 30 to
36) months on cART). In some individuals, analyses were
performed additionally at enrolment, during the first year and
after more than 4 years on successful cART. We restricted our
analyses to individuals infected with HCV-genotype 1 (n¼73) or
3 (n¼46). For cellular analyses we also included individuals with
spontaneous HCV clearance (n¼22) of unknown HCV genotype
(genotyping was not possible because clearance had already
occurred when entering the SHCS). Spontaneous HCV clearance
was defined as HCV seropositivity and undetectable HCV-RNA.
All analyses were before HCV therapy. Table 1 shows the
characteristics of the study participants. Figure 1 shows the
number of individuals with available viable cells and/or plasma
samples at each time-point, and the median CD4+ T cell counts
and HIV-RNA levels at these time-points.
Laboratory methods
Cellular assays
Peptides and proteins
We used the same experimental approach as in previous studies to
investigate the influence of cART on HCV-specific T cell immu-
nity.9We have shown in several studies, that responses to the core
peptides are reproducibly detectable in a reasonable fraction of
patients, that these are dominated by CD4+ Tcell responses, and
that they are rarely associated with virus escape.9 20e22 Core
peptides are therefore ideally suited to assess the influence of cART
onHCV-specific Tcell responses. TheHCVantigens were 18HCV
core genotype 1 specific sequence peptides (20mers overlapping by
10) that cover amino acids 1e191 and were pooled to a final
concentration of 10 mg/ml of each peptide. To further investigate
whether the change in immune responses to cART was only
restricted to core peptides, we included the recombinant HCV
non-structural (NS) proteins NS3, NS4 and NS5. These proteins
have been shown to induce immune responses especially during
acute HCV infection or in individuals with spontaneous HCV
clearance.23 24 The recombinant HCV genotype 1 proteins NS3,
NS4 and NS5 were pooled to a final concentration of 1 mg/ml for
each antigen in the ELISpot assay. We used pooled recombinant
NS proteins instead of overlapping peptides, as these predomi-
nantly stimulate CD4+ T cell responses and to maximise the
detection rate from fairly limited cell numbers. RecombinantHIV-
p24 antigen, EBVandCMVcontrol peptideswere used at the same
concentration of 1 mg/ml.
ELISpot assay for interferon g secretion
ELISpot assays were performed as previously described.9 PBMCs
(100 000 per well) were used and plates were read with an AID
plate reader. Each sample was tested in duplicate against HCV
antigens, HIV-p24, EpsteineBarr virus (EBV) and cytomegalo-
virus (CMV) antigens. Phytohaemagglutinin (PHA) was used as
Table 1 Demographic characteristics
Characteristics N (%)
Total* 141
Chronic HCV infection 119 (84)
Cleared HCV infection 22 (16)
Sex
Male 94 (67)
Female 47 (33)
Ethnicity
Caucasian 134 (95)
Non-Caucasian 7 (5)
Transmission mode
Intravenous drugs 103 (73)
Heterosexual 30 (21)
MSM 5 (4)
Haemophilia 3 (2)
Age, median (IQR) 38 (34e42)
*Number of individuals with $1 viable peripheral blood mononuclear
cells and/or plasma sample.
HCV, hepatitis C virus; MSM, men who have sex with men.
Figure 1 Study population, CD4+ T cell counts and HIV-RNA levels.
Median CD4+ T cell counts and HIV-RNA levels at the different study
time-points are shown. The table below the graph indicates the number
of individuals with available viable peripheral blood mononuclear cells for
cellular assays, and with plasma samples for the measurement of
hepatitis C virus (HCV) RNA levels. cART, combination antiretroviral
therapy.
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a positive control. Samples without any detectable PHA
response were excluded. A test was considered positive if the
probability of a spot appearing in the test well was significantly
different (p#0.05) from the probability of a spot appearing in
the control well (background), assuming a binominal distribu-
tion for each test antigen (Excel BINOMDISTstatistics program,
Microsoft). The mean number of spot forming units (SFU) in
control wells was subtracted from the mean SFU number in the
test wells to give a final reading.
HCV RNA measurement
RNA extraction
For the preparation of RNA from plasma samples we used the
EasyMag Magnetic extraction kit according to the manufac-
turer ’s instructions (Biomérieux, Geneva, Switzerland). In brief
200 ml of plasma was incubated with 2 ml lysis buffer containing
guanidinthiocyanate and 2.5 ml carrier RNA (1 mg/ml) for 10 min
at room temperature. After adding 550 ml NucliSens easyMAG
magnetic silica and incubation for another 10 min at room
temperature, several wash steps (using NucliSens easyMAG
extraction buffer 1 and 2) were performed, and finally the
purified RNAwas eluted with 110 ml NucliSens extraction buffer
3. HCV RNA standards were obtained from AcroMetrix (Opti-
Quant HCV RNA quantification panel, AcroMetrix,
Netherlands) and extracted according to the same procedure as
described above, together with clinical samples.
Viral load assay
Based on the method previously published by Castelain et al,25
a real-time RT-PCR assay using TaqMan (fluorescence-based
real-time PCR) and minor groove binding (MGB) probes was
designed for quantitative determination of HCV RNA in clinical
samples. The specific reverse transcription of HCV was
performed in 20 ml reaction mixture containing 10.5 ml of eluted
RNA and reverse transcription reagents including MultiScribe
TM reverse transcriptase, dNTP(2.5 mM), MgCl2 (2.5 mM),
103 buffer with RNAsin (20 U/ml), and random hexamers
(Applied Biosystems, Rotkreuz, Switzerland). The products
were hybridised by incubating at 258C for 10 min, incubated at
488C for 30 min for reverse transcription, followed by heating to
958C for 5 min to deactivate the reverse transcriptase. To
increase specificity, a second round of reverse transcription at
a higher temperature and subsequent cDNA amplification was
performed using 96-well plates in duplicate reactions requiring
6 ml of cDNA template in 20 ml reactions containing rTH DNA
polymerase (2.5 U/ml), AmpErase UNG, dATP, dGTP, dCTP,
dUTP and a 53 buffer containing a passive reference (6-
carboxyrhodamine labelled with ROX) (EZ-RT PCR kit, Applied
Biosystems, Rotkreuz, Switzerland) forward primer (500 nM)
HCV-S1 (nucleotides: 127 to 145; 59-TCCCGGGAGAGCC-
ATAGTG-39), reverse primer (1 mM) HCV-AS2 (nucleotides:
202 to 185; 59-TCCAAGAAAGGACCCRGT-39) and 1 mM
TaqMan minor groove binding (MGB) probe labelled with
6-carboxyfluorescein (nucleotides: 147 to 161; 59-FAM-
TCTGCGGAACCGGTG-MGB-39).
The ABI 7900 HT real-time PCR detection system (Applied
Biosystems) was used for analysis. Thermal cycling conditions
were designed as follows: 508C for 2 min, for contamination
control with AmpErase UNG, followed by 608C for 30 min for
continued reverse transcription with rTH DNA polymerase,
then 958C for 15 sec and 608C for 60 sec. Fluorescent measure-
ments were recorded during each annealing step. At the end of
each PCR run, data were automatically analysed by the system
and amplification plots were generated. The HCV copy number
was determined by reading from the standard curve (OptiQuant
HCV RNA quantification panel, AcroMetrix, Netherlands, range
50 to 5 Mio IU/ml). Mean cycle threshold (CT) values for the
main range of HCV RNA levels (5 to 7 log10 IU/ml) were 28.5
(SD60.5), 25.2 (SD60.5) and 23.5 (SD60.1). To avoid inter-
assay variability, all samples from one patient were measured
within the same assay. The standard transcripts, the controls
and all study samples were run in duplicate. Replicate samples
varying by more than 5% of their quantification cycle were
repeated. To assess inter-assay variability, we included in each
run plasma from one individual with a known HCV RNA level
(5.0 log10 IU/ml, assessed by the Roche Cobas assay). RNA levels
from this individual measured by our in-house assay were
comparable and showed low inter-assay variability over 15 runs
(mean quantity 5.1 (SD60.25) log10 IU/ml). In addition, control
plasma samples with a wide range of HCV RNA levels provided
by Roche Diagnostics, Switzerland, were included in each run
and also showed low inter-assay variability in both the low and
high range (mean quantity 2.1 (SD60.3) and 5.1 (SD60.2)
log10 IU/ml, respectively). HCV-negative plasma sample
obtained from AcroMetrix (OptiQuant HCV RNA quantifica-
tion panel, AcroMetrix, Netherlands) and distilled water were
included as non-template controls in every run. All negative
controls were always amplified after CT values of 40.
Statistical analysis
Cross-sectional comparisons were performed using a robust
variance estimation model for cluster-correlated data to consider
data points representing repeated measurements.26 Longitudinal
analyses were done by using the non-parametric paired
Wilcoxon signed rank test. Statistical analyses were performed
in STATA V.10.0 software and the figures were drawn using
Graphpad Prism 5.01 software.
RESULTS
HCV-specific T cell responses to HCV core peptides
We quantified longitudinally HCV-specific T cell responses to
HCV core peptides by ex vivo interferon g (IFNg) ELISpot
assays in untreated and treated HIV infection. In cross-sectional
analyses, the proportion of individuals with detectable HCV-
specific immune responses to HCV core peptides was signifi-
cantly higher during successful cART compared to untreated
HIV infection (figure 2A). During untreated HIV infection there
was no significant change in HCV-specific immune responses
(13% (2/16) vs 19% (12/64), p¼0.54). However, during
successful cART, the proportion of individuals with detectable T
cell responses increased significantly: 24% (12/50) during the
first year, 45% (29/64) after more than 3 years and 49% (18/37)
after more than 5 years of successful cART (p¼0.001). Accord-
ingly, the frequency of spot forming cells was significantly
higher after initiation of HIV therapy (figure 2B). The increase in
responses to HCV core peptides on cART was observed for
chronic and spontaneously cleared HCV infection (figure 2D)
and for both HCV genotypes (figure 2C). This is in line with the
high sequence similarity of the HCV core region with 94%
identity between genotypes 1 and 3.27
Neither CD4+ Tcell counts at the time of the experiments nor
nadir CD4+ T cell counts correlated significantly with the
presence or absence of HCV-specific T cell responses (p>0.1 for
all comparisons). At baseline, the relative CD4+ Tcell count was
higher in individuals with detectable HCV-specific T cell
responses to HCV core peptides, compared to those without
detectable responses (22% vs 15%, p¼0.05), while there was no
Rohrbach J, Robinson N, Harcourt G, et al. Gut (2010). doi:10.1136/gut.2009.205971 3 of 7
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statistically significant difference with regard to absolute CD4+
T cell counts. There was no significant correlation of relative or
absolute CD4+ T cell counts with HCV-specific T cell responses
after starting cART.
In a subgroup of 54 individuals (supplementary table 1) with
available viable PBMCs 0.8 months before starting HIV therapy
and after a median of 33 months on successful cART, we
assessed longitudinally the evolution of HCV-specific T cell
responses. The proportion of individuals with detectable T cell
responses and the frequency of IFNg producing Tcells increased
significantly during cART (22% vs 44%, p¼0.02) (supplementary
figure 1). Emergence of detectable T cell responses was much
more frequent than loss of responses during cART (31% vs 9%).
Individuals with increases in immune responses had lower
CD4+ Tcell counts at baseline compared to individuals without
detectable T cell responses to HCV core peptides pre- and on-
cART (150 vs 225 CD4+ T cells/ml; p¼0.03). However, this
difference was driven by two individuals with increases in Tcell
responses who started cART with CD4+ T cell counts below
5 cells/ml, and the relevance of this difference remains uncertain.
For the remaining characteristics, there were no significant
differences among the four groups.
T cell responses to further peptides
In contrast to the responses to HCV core peptides, there was
no significant change in the response to recombinant HCV
NS3-5 proteins. From the 48 individuals with at least one
response to HCV core peptides, 11 (23%) also responded to
Figure 2 T cell ELISpot responses to hepatitis C virus (HCV) core peptides before and on successful combination antiretroviral therapy (cART). The
proportion of individuals with detectable ELISpot responses to HCV core peptides increased significantly during successful cART (A). Peak frequency of
interferon-g producing T cells per million peripheral blood mononuclear cells recognising HCV-core peptides significantly increased after initiation of
a successful cART (B). The increase in responses to HCV core peptides on cART was observed for chronic (C) and spontaneously cleared HCV infection
(D) and for both HCV genotypes (C). Only p-values <0.05 are shown. SFC, spot forming cells.
Figure 3 Proportion of individuals with
detectable ELISpot responses to
hepatitis C virus (HCV) core peptides
and to different control peptides.
Arrows denote the time-point of start of
combination antiretroviral therapy
(cART). ND, no data.
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NS3-5 peptides. Conversely, 11 of 12 (92%) individuals with
responses to NS3-5 proteins also responded to core peptides.
This is in line with previous findings that responses to core
proteins are detected more frequently than responses to NS
proteins.9 23 Although some NS3-5 epitopes are shared between
genotype 1 and 3 sequences,28e30 other epitopes are clearly
genotype-specific.29 31 Therefore, it is likely that some genotype
3 specific responses to the NS proteins were missed. Responses
to HIV-p24 decreased, while responses to CMV peptides
increased significantly during cART (p¼0.001). Twenty-eight of
the 48 (58%) individuals with responses to HCV core peptides
also responded to CMV peptides.
HCV RNA levels
HCV-RNA levels were evaluated in 119 HIV/HCV coinfected
individuals. In cross-sectional analysis, median HCV RNA levels
during untreated HIV infection were 6.3 (IQR 5.6e6.8) log10 IU/
ml at enrolment and 6.5 (IQR 5.9e7.0) log10 IU/ml just before
starting cART. During the first year on successful cART, median
HCV-RNA levels slightly increased to 6.6 (IQR 6.0e7.2)
log10 IU/ml. During long-term cART, median HCV-RNA levels
decreased to 6.4 (IQR 5.9e6.9) and 6.2 (IQR 5.6e6.7) log10 IU/
ml after 3 and 5 years, respectively (figure 4A). HCV clearance
was not observed despite long-term cART.
In individuals with longitudinal samples during untreated
HIV infection, the median change in HCV-RNA levels was +0.4
log10 IU/ml. In the first year on successful cART, there was
a slight increase of HCV-RNA levels (+0.1 log10 IU/ml). During
long-term cART, median HCV-RNA levels slightly decreased
compared to pre-cART levels (0.3 log10 IU/ml, p¼0.02; figure 4B).
HCV RNA levels slightly decreased on successful cART in both
HCV-genotype 1 (0.2 log10 IU/ml) and HCV-genotype 3
infected individuals (0.3 log10 IU/ml). The increase in absolute
CD4+ T cell counts on successful cART was not significantly
associated with the change in HCV RNA levels (p¼0.1).
In the subgroup of individuals with increasing HCV-specific
immune responses a more marked decline of HCV-RNA levels
on cART, we observed compared to individuals without any
detectable ELISpot responses to HCV-core peptides (figure 5). In
individuals with increasing HCV-specific T cell responses to
HCV-core peptides, the median HCV RNA change from baseline
was 0.5 and 0.8 log10 IU/ml. For individuals without T cell
responses, the median change from baseline after 3 and 5 years
of successful cART was 0.2 and 0.1 log10 IU/ml. However,
these differences were not statistically significant.
DISCUSSION
Coinfection with HIV substantially diminishes the immuno-
logical control of HCV. Previous studies have shown that HCV-
specific immune responses are reduced in HIV infected individ-
uals.8 9 11 Furthermore, the high HCV RNA levels observed in
HIV infected individuals indicate a loss of control of HCV
replication.1 Here, we show that successful cART partially
restores T cell responses to HCV-core peptides. The proportion
of individuals with detectable immune responses on long-term
cART (49%) was very similar to that observed by Harcourt et al
in HCV monoinfected individuals (52%) using the same exper-
imental approach.9 A successful cART also increased cellular
immune response to HCV core peptides in individuals that
spontaneously cleared HCV infection. This finding is in line
with the observation that cellular immunity is maintained long
term in individuals who spontaneously clear infection.32
Wehave shownpreviously usingCD8+Tcell depletedPBMCs,20
in addition to previous experiments using flow cytometry,22 33
that the largemajority of responses to theHCVantigens used here
were fromCD4+ Tcells. Therefore, the measured increase in Tcell
responses largely represents CD4+ T cell reactivity. High sensi-
tivity techniques to isolate T cell subsets would have required
larger cell numbers and ideally fresh samples, that were not
available due to the long-term follow-up in this study.
The absence of a significant increase in responses to HCV
NS3-5 proteins in our HIV/HCV coinfected patients is in
accordance with previous studies where these responses were
not detectable in the majority of HCV monoinfected individ-
uals.9 Non-structural HCV proteins are highly polymorphic and
the consensus sequence that is used to generate the peptide
libraries contains in many instances escaped variants that are
poorly immunogenic.31 34 35 Viral adaptation to T cell pressure
through mutational escape is more likely in polymorphic
proteins, which might explain why T cell responses to NS3-5
peptides are more difficult to detect compared to responses to
the conserved core peptides. Because we used different methods
(core peptides versus non-structural proteins), the responses to
core and NS are not directly comparable. However, a comparison
of the relative importance of immune responses to different
peptides and proteins was beyond the scope of this study.
Instead, we used an optimised, reproducible and well studied
approach to investigate the influence of cART on the evolution
of T cell responses. Future studies are underway and will aim to
assess the relationship between responses to structural and non-
structural gene products in more detail.
Concurrently with the increase of cellular immune responses
during cART, we observed a slight but significant decrease in
HCV RNA levels. This effect was particularly evident in a small
Figure 4 Impact of combination antiretroviral therapy (cART) on
hepatitis C virus (HCV) RNA levels. Median HCV RNA levels at the
different study time-points are shown in (A) in cross-sectional analysis.
The change in HCV RNA levels within individuals in untreated and treated
HIV infection is outlined in (B). Only p-values #0.1 are shown.
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subgroup of individuals with increasing HCV specific immune
responses. The temporal association of increasing HCV specific
T cell responses and decreasing HCV RNA levels might poten-
tially indicate that immune reconstitution through successful
cART improves the control of HCV replication, although it is
difficult to show cause and effect in this case. A transient
increase in HCV RNA levels during the first year of cART has
been observed previously (reviewed in Cooper and Cameron17).
Suggested mechanisms for such an increase include increased
hepatocyte lysis through restored T cell immunity, and
a decrease in interferon levels through treatment of HIV.15
Clearance of HCV infection during cART has been reported in
only a few cases.36e41 We did not observe HCV clearance despite
a substantial increase in T cell responses on cART. This suggests
that in most cases, immunological HCV clearance cannot be
achieved by restoring T cell responses through successful cART.
Our study has strengths and limitations. A main strength is
the long-term follow-up and the longitudinal setting that largely
avoids confounding through clinical and demographic charac-
teristics. Additionally, we could assess cellular immune
responses and HCV RNA levels in the same cohort and therefore
simultaneously evaluate the impact of HIV and cART on T cell
responses and viral loads. Through the restriction to successful
and uninterrupted cART, we could avoid biases through treat-
ment failures and interruptions. A limitation of the study is the
restriction of cellular experiments through the use of stored
PBMCs. Due to the limited number of frozen PBMCs, we could
not assess CD8+ or regulatory T cell responses, or perform an
in-depth analysis of HLA-restricted immune responses. In addition
viable cells and/or plasma were not available for all participants
at all study time-points. We acknowledge that we might have
missed many HCV specific Tcell responses that could have been
detected after in vivo culture, as shown recently.24 However, we
explicitly wanted to assess the influence of an increased immune
pressure in-vivo and therefore avoided additional in-vitro stim-
ulation that can strongly influence Tcell responses, as shown by
Schnuriger et al.24 Additional culturing could have masked the
main study question about the effects of cARTon HCV-specific
T cell reactivity. Ex-vivo ELISpot responses probably underesti-
mate the total number of HCV-specific cells that can be gener-
ated after culturing. However, this does not alter the main
conclusion that cARTcan increase HCV-specific Tcell responses.
As HCV specific T cell responses were not detectable in most
individuals, we could not reliably correlate changes in the
frequency of T cell responses with HCV RNA levels and estab-
lish possible cause and effect.
Our findings are in line with the beneficial clinical effects of
cART on the natural course of hepatitis C in HIV infected
individuals 13 14 and with the current recommendation to start
cART earlier in HCV/HIV coinfected individuals.42 43 However,
it remains unclear to what extent the increases in cellular
immune responses during cART result in beneficial effects on
liver disease progression. Other favourable effects of cART on
liver disease include a reduction in immune activation and in
bacterial translocation. Although one study found that higher
hepatitis C RNA levels were associated with increased mortality
from end stage liver disease,44 most reports did not find a corre-
lation between HCV RNA levels and liver disease.45 46 It is
therefore unlikely that the modest effect of cART on HCV
viraemia results in large clinical effects. However, as viral load is
an important predictor of the response to HCV therapy,47
a reduction in HCV RNA levels through cART might result in
better response rates to HCV therapy. Future studies should
clarify whether starting cART early in the course of HIV infec-
tion would lower the risk of progression to end-stage liver
disease and improve HCV treatment responses.
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